Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696398 | 1.00 | KMT2A (0.42) | KMT2AHTTALDH1A1ALOX15TSHR | |
| SCHEMBL2148865 | 0.82 | ALDH1A1 (0.47) | KMT2AALDH1A1ALOX15TSHR | |
| SCHEMBL3801584 | 0.78 | KMT2A (0.42) | KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1182747 | 0.74 | ALDH1A1 (0.39) | HTTALDH1A1ALOX15TSHRLMNA | |
| SCHEMBL3444583 | 0.74 | ALDH1A1 (0.39) | KMT2AHTTALDH1A1ALOX15TSHR | |
| SCHEMBL30696400 | 0.74 | LMNA (0.52) | KMT2AHTTALDH1A1ALOX15TSHR | |
| SCHEMBL11775855 | 0.74 | LMNA (0.52) | KMT2AHTTALDH1A1ALOX15TSHR | |
| SCHEMBL31484438 | 0.74 | KMT2A (0.44) | KMT2AHTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3784217 | 0.71 | DPP4 (0.37) | KMT2ALMNA | |
| SCHEMBL10603143 | 0.70 | PDE10A (0.52) | HTTALDH1A1ALOX15TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3630751-B1 | CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS | NOVARTIS AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| CN-110944995-B | Crystalline forms of 5-bromo-2, 6-di (1H-pyrazol-1-yl) pyrimidin-4-amine and novel salts | 诺华股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| EP-2552909-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2013-02-06 | — | — | EP | disclosed |
| CN-102892761-A | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | PALOBIOFARMA SL | 2013-01-23 | — | — | CN | disclosed |
| WO-2012170647-A1 | PROCESS FOR THE PREPARATION OF ETRAVIRINE AND INTERMEDIATES IN THE SYNTHESIS THEREOF | ASSIA CHEMICAL INDUSTRIEW LTD. (IL) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170647-A1 | PROCESS FOR THE PREPARATION OF ETRAVIRINE AND INTERMEDIATES IN THE SYNTHESIS THEREOF | ASSIA CHEMICAL INDUSTRIEW LTD. (IL) | 2012-12-13 | — | — | WO | disclosed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | KMT2A 1114/4885HTT 4612/4885ALDH1A1 369/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | KMT2A 1683/4885HTT 955/4885ALDH1A1 788/4885 |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KMT2A 1923/4885HTT 2281/4885ALDH1A1 347/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KMT2A 1923/4885HTT 2281/4885ALDH1A1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.